Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2022 May 10

PMID 35536859

Authors

Liang Qin

Yoon-Mi Chung

Michael Berk

Bryan Naelitz

Ziqi Zhu

Eric Klein

Abhishek A Chakraborty

Nima Sharifi

Affiliations

Soon will be listed here.

Abstract

Significance: Hypoxia followed by reoxygenation in prostate cancer drives androgen deprivation therapy resistance via increasing the rate-limiting enzyme and cofactors for androgen synthesis, revealing HIF2α as a therapeutic target to subvert resistance.

Citing Articles

Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.

Sharifi N, Diaz R, Lin H, Roberts E, Horvath L, Martin A J Clin Invest. 2024; 134(18).

PMID: 39286977 PMC: 11405037. DOI: 10.1172/JCI183583.

HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.

Sharifi N, Azad A, Patel M, Hearn J, Wozniak M, Zohren F Cell Rep Med. 2024; 5(8):101644.

PMID: 39168093 PMC: 11384952. DOI: 10.1016/j.xcrm.2024.101644.

Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression.

Qin L, Berk M, Chung Y, Cui D, Zhu Z, Chakraborty A Cell Rep. 2024; 43(1):113575.

PMID: 38181788 PMC: 10851248. DOI: 10.1016/j.celrep.2023.113575.

References

Thomas J, Duax W, Addlagatta A, Brandt S, Fuller R, Norris W . Structure/function relationships responsible for coenzyme specificity and the isomerase activity of human type 1 3 beta-hydroxysteroid dehydrogenase/isomerase. J Biol Chem. 2003; 278(37):35483-90. DOI: 10.1074/jbc.M304752200. View

Fraga A, Ribeiro R, Principe P, Lopes C, Medeiros R . Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings. Clin Genitourin Cancer. 2015; 13(4):295-301. DOI: 10.1016/j.clgc.2015.03.006. View

Goda N, Ryan H, Khadivi B, McNulty W, Rickert R, Johnson R . Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol. 2002; 23(1):359-69. PMC: 140666. DOI: 10.1128/MCB.23.1.359-369.2003. View

Ranasinghe W, Baldwin G, Bolton D, Shulkes A, Ischia J, Patel O . HIF1α expression under normoxia in prostate cancer--which pathways to target?. J Urol. 2014; 193(3):763-70. DOI: 10.1016/j.juro.2014.10.085. View

Desai M, Parsi M, Potdar R . Triple-arm androgen blockade for advanced prostate cancer: a review. Med Oncol. 2021; 38(7):75. DOI: 10.1007/s12032-021-01520-y. View

Maranchie J, Vasselli J, Riss J, Bonifacino J, Linehan W, Klausner R . The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 2002; 1(3):247-55. DOI: 10.1016/s1535-6108(02)00044-2. View

Kruse M, Patel M, McManus J, Chung Y, Li X, Wei W . Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. JCI Insight. 2021; 6(20). PMC: 8564898. DOI: 10.1172/jci.insight.150403. View

Deep G, Panigrahi G . Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment. Crit Rev Oncog. 2016; 20(5-6):419-34. PMC: 5308872. DOI: 10.1615/CritRevOncog.v20.i5-6.130. View

Eales K, Hollinshead K, Tennant D . Hypoxia and metabolic adaptation of cancer cells. Oncogenesis. 2016; 5:e190. PMC: 4728679. DOI: 10.1038/oncsis.2015.50. View

10.

Attard G, Parker C, Eeles R, Schroder F, Tomlins S, Tannock I . Prostate cancer. Lancet. 2015; 387(10013):70-82. DOI: 10.1016/S0140-6736(14)61947-4. View

11.

Qi J, Nakayama K, Cardiff R, Borowsky A, Kaul K, Williams R . Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell. 2010; 18(1):23-38. PMC: 2919332. DOI: 10.1016/j.ccr.2010.05.024. View

12.

Ratnadiwakara M, Anko M . mRNA Stability Assay Using transcription inhibition by Actinomycin D in Mouse Pluripotent Stem Cells. Bio Protoc. 2021; 8(21):e3072. PMC: 8342049. DOI: 10.21769/BioProtoc.3072. View

13.

Ashton J, Bristow R . Bad neighbours: hypoxia and genomic instability in prostate cancer. Br J Radiol. 2020; 93(1115):20200087. PMC: 8519639. DOI: 10.1259/bjr.20200087. View

14.

Chang K, Li R, Papari-Zareei M, Watumull L, Zhao Y, Auchus R . Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2011; 108(33):13728-33. PMC: 3158152. DOI: 10.1073/pnas.1107898108. View

15.

Zhu Z, Chung Y, Sergeeva O, Kepe V, Berk M, Li J . Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging. J Biol Chem. 2018; 293(46):17829-17837. PMC: 6240862. DOI: 10.1074/jbc.RA118.004846. View

16.

Cho H, Du X, Rizzi J, Liberzon E, Chakraborty A, Gao W . On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature. 2016; 539(7627):107-111. PMC: 5499381. DOI: 10.1038/nature19795. View

17.

Sharifi N . Minireview: Androgen metabolism in castration-resistant prostate cancer. Mol Endocrinol. 2013; 27(5):708-14. PMC: 3634114. DOI: 10.1210/me.2013-1007. View

18.

Gordan J, Lal P, Dondeti V, Letrero R, Parekh K, Oquendo C . HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008; 14(6):435-46. PMC: 2621440. DOI: 10.1016/j.ccr.2008.10.016. View

19.

Hearn J, Sweeney C, Almassi N, Reichard C, Reddy C, Li H . HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncol. 2020; 6(4):e196496. PMC: 7042830. DOI: 10.1001/jamaoncol.2019.6496. View

20.

Chen W, Hill H, Christie A, Kim M, Holloman E, Pavia-Jimenez A . Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016; 539(7627):112-117. PMC: 5340502. DOI: 10.1038/nature19796. View